Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
32.32
-0.37 (-1.13%)
Feb 21, 2025, 4:00 PM EST - Market closed
Ionis Pharmaceuticals Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for Ionis Pharmaceuticals stock have an average target of 61.24, with a low estimate of 37 and a high estimate of 77. The average target predicts an increase of 89.48% from the current stock price of 32.32.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Ionis Pharmaceuticals stock from 19 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 6 |
| Buy | 6 | 6 | 7 | 7 | 7 | 7 |
| Hold | 6 | 6 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 18 | 18 | 18 | 18 | 18 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $67 → $64 | Strong Buy | Maintains | $67 → $64 | +98.02% | Feb 20, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $70 | Buy | Reiterates | $70 | +116.58% | Feb 20, 2025 |
| BMO Capital | BMO Capital | Hold Maintains $60 → $45 | Hold | Maintains | $60 → $45 | +39.23% | Feb 20, 2025 |
| Needham | Needham | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +85.64% | Feb 20, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $70 | Buy | Reiterates | $70 | +116.58% | Jan 15, 2025 |
Financial Forecast
Revenue This Year
630.83M
from 787.65M
Decreased by -19.91%
Revenue Next Year
694.39M
from 630.83M
Increased by 10.08%
EPS This Year
-3.55
from -2.56
EPS Next Year
-3.86
from -3.55
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 706.2M | 1.0B | 1.6B | |||
| Avg | 630.8M | 694.4M | 942.7M | |||
| Low | 584.1M | 423.8M | 674.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -10.3% | 62.0% | 126.7% | |||
| Avg | -19.9% | 10.1% | 35.8% | |||
| Low | -25.8% | -32.8% | -2.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -3.19 | -2.46 | -1.38 | |||
| Avg | -3.55 | -3.86 | -2.83 | |||
| Low | -3.66 | -5.07 | -4.15 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.